Urtė Fultinavičiūtė

As Pfizer continues to focus on its commercial execution, the pharma giant placed biosimilars and sterile injectables under a new dedicated division.

Celltrion's “young” products accounted for 60% of quarterly revenues, with further growth opportunities expected in the second half of 2026.

Holders of dormant marketing authorizations identified by the UK's Project Revive and interested in participating in the pilot must complete their applications before June 1.

Profitable growth over market share grabs, a capacity-doubled Malaysia facility and a succession plan in the making: Biocon is quietly reshaping itself for the long haul.

Lupin hit $1bn in US sales once before but then spent years clawing its way back. Now it's back, bigger, and betting biosimilars will keep the momentum going.

With a US launch window locked in for Q4 2026 and Europe already live, Formycon is converting years of development and deal-making into commercial momentum.

Olayan Financing Company's minority stake gives MS Pharma both the cash and the local network it needs to turn an ambitious MENA biosimilar strategy into real market presence in 2026.

The deal for an undisclosed biosimilar with Argentina-based Tuteur gives Polpharma Biologics regional commercial coverage across most of Latin America.

Online health platform Hims & Hers will sell Apotex's generic semaglutide in Canada but is only offering off-label prescriptions for weight loss.

A favorable appeal ruling gives Outlook Therapeutics its clearest US regulatory signal yet, but with $7.7m in cash and European sales sliding, the timing has never mattered more.